Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report
Summary
The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization.
Scope
- This report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry’s most comprehensiv
Read More
- Table of Contents
- 1. Market Cap Change for Bio/Pharma Companies in Q1 2020
- Market Cap for Bio/Pharma Companies With and Without a COVID-19 Drug over Q1 2020
- Q1 2020 Change in Market Cap by Company Market Cap Size
- 2. Market Cap for Top 20 Bio/Pharma Companies: Q1 2020 vs. 2019
- Market Cap Change for Top 20 Bio/Pharma: Q1 2020 vs. 2019
- Market Cap Change Q1 2020: Bayer AG
- Market Cap Change Q1 2020: Gilead Sciences
- Market Cap Change Q1 2020: Regeneron Pharmaceuticals
- Q1 2020 Market Cap Change for Top
Read More